{
    "clinical_study": {
        "@rank": "144611", 
        "arm_group": {
            "arm_group_label": "Autoinjector A", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the ability of people with Rheumatoid Arthritis or\n      Psoriatic Arthritis to use an experimental autoinjector to self inject etanercept (Enbrel\u00ae).\n      Study participants need to have been self-administering etanercept for greater than or equal\n      to 6 months prior to screening. You will be in this study for about 9 weeks. This includes a\n      4-week screening period and a 5-week treatment period."
        }, 
        "brief_title": "Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Rheumatoid Arthritis", 
            "Psoriatiric Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Subject has diagnosis of RA or PsA and indicated for treatment with\n        etanercept per the current label, based on history. -  Subject is willing to self-inject\n        per investigator judgement at screening. - Subject has no known history of tuberculosis.\n\n        - Exclusion Criteria: Latex allergy. - Subject has any active infection (including chronic\n        or localized infections) for which anti-infectives were indicated within 4 weeks prior to\n        first study dose of etanercept. - Subject had prosthetic joint infection within 5 years of\n        screening or native joint infection within 1 year of screening. - Other criteria may\n        apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "77", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901185", 
            "org_study_id": "20110107"
        }, 
        "intervention": {
            "arm_group_label": "Autoinjector A", 
            "intervention_name": "Etanercept", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 21, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35801"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85381"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85037"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Maria", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93454-6945"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Upland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91786"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80230"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34239"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33614"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paducah", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "42003"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68516"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orchard Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14127"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73103"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechancial Autoinjector to Self-inject Etanercept", 
        "other_outcome": {
            "measure": "Number of subject reports of adverse events, serious adverse events and adverse device events", 
            "safety_issue": "Yes", 
            "time_frame": "Weekly for 5 weeks at Week 1, Week 2, Week 3, Week 4 and Week 5"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Successful self-injection of etanercept using Autoinjector A, as evaluated by the proportion of successful injections of the total nonmissed injections administered by subjects in the non-health care setting", 
            "safety_issue": "Yes", 
            "time_frame": "Weekly for 5 weeks at Week 1, Week 2, Week 3, Week 4 and Week 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901185"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Autoinjector A system failure when the Autoinjector A system is operated within intended use", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 5 weeks at Week 1, Week 2, Week 3, Week 4 and Week 5"
            }, 
            {
                "measure": "Proportions of the unsuccessful steps in the self-injection process for unsuccessful injections, as assessed by the Participant Self-injection Questionnaire (Questions 2 to 5).", 
                "safety_issue": "No", 
                "time_frame": "Weekly for 5 weeks at Week 1, Week 2, Week 3, Week 4 and Week 5"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}